7:["$","$L18",null,{"data":{"project_id":null,"showcase_id":1497,"assistant_id":"asst_l2v9gb34YOQr3Es4jf3WYpPF","enable_curation_ai":true,"agent_id":null,"intent":null,"title":"Genus","description":"Genus is a global leader in animal genetics, specializing in porcine (PIC) and bovine (ABS) breeding solutions.","type":"text","private_showcase":false,"logo":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1739872140.jpeg","x_link":null,"showcase_heading":"Gen(i)us in the making","executive_summary_title":"A Global Leader in Animal Genetics","executive_summary":"

Genus is a global leader in animal genetics, specializing in porcine (PIC) and bovine (ABS) breeding solutions. Through advanced technologies such as gene editing, genomic selection, and proprietary breeding algorithms, Genus empowers livestock producers to enhance productivity, improve herd health, and drive sustainable agricultural practices. With operations spanning key global markets, the company is at the forefront of delivering genetic innovations that address food security challenges and reduce environmental impact.

The investment case for Genus is underpinned by three key pillars: its market leadership in porcine genetics through PIC, a robust recovery trajectory for its ABS division, and the transformative potential of its PRRS-resistant pig (PRP) technology.

","investor_relations_link":"https://www.genusplc.com/investors/overview/","investor_relations_label":"Investor Relations","graph_link":"https://jika.io/embed/area-chart?symbol=GNS.L&selection=one_year&closeKey=close&boxShadow=true&graphColor=1652f0&textColor=161c2d&backgroundColor=FFFFFF&fontFamily=Nunito","contact_email":"nirav.karia@curationcorp.com","slug":"Genus-24053","status":"in-progress","usp_cta":null,"usp_cta_link":null,"catalyst_cta":null,"catalyst_cta_link":null,"teaser_video":"https://www.youtube.com/watch?v=phZgq8n9J4Y&","teaser_video_iframe_url":"https://www.youtube.com/embed/phZgq8n9J4Y?start=undefined","teaser_video_label":"Watch Video","teaser_video_title":null,"teaser_video_caption":null,"x_link_label":null,"hero_caption":"Genus: Pioneering Genetic Solutions for Sustainable Agriculture and Livestock Health","hero_cta_label":"+Watchlist","hero_cta_link":"https://app.curationconnect.com/account/signup","hubspot_enabled":false,"disclaimer":null,"discovery_cover_image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1741184835.jpeg","discovery_caption":"Coming soon","updated_at":"2025-05-02 12:33:10","usps":[{"title":"PIC continues to take market share","description":"

PIC has achieved notable market share gains, driven by technological advancements and strategic market positioning. Over the past five years, PIC has increased its global market share by over 5% to c.35%, with a particularly strong performance in China, where royalty-based models have provided consistent, high-margin revenues. In Latin America, revenue has grown at a double-digit CAGR, fueled by expanding partnerships with major producers.

Looking ahead, analysts project PIC’s market share could increase by another 7-10% over the next five years, supported by continued expansion in emerging markets, adoption of digital breeding platforms, and growing demand for disease-resistant genetics. These advancements are expected to deliver sustainable, long-term growth with recurring royalty-based income.

","video":null,"video_iframe_url":null},{"title":"ABS is showing clear signs of a turnaround","description":"

ABS, which had been underperforming due to operational inefficiencies and market competition, is now showing clear signs of a turnaround. The division previously struggled with margin compression and sluggish growth, but operational improvements under the Value Acceleration Programme (VAP) are reversing this trend. Phase I of VAP has delivered £10m in annualized cost savings, and Phase II is projected to add another £10m through enhanced supply chain efficiency and digital customer engagement.

Increased adoption of IntelliGen technology, which enables precise sexed-semen solutions, has been pivotal in driving productivity for customers. Additionally, strong demand for beef-on-dairy programs, particularly in North and Latin America, is boosting volumes. Combined with expansion into emerging markets in Asia and Latin America, ABS is firmly on a path to sustainable recovery and growth.

","video":null,"video_iframe_url":null},{"title":"PRP: A Game-Changer","description":"

The PRRS-resistant pig (PRP) is a breakthrough genetic innovation designed to combat Porcine Reproductive and Respiratory Syndrome (PRRS), a disease that causes billions in losses annually to the pork industry.

PRP uses targeted gene editing to eliminate susceptibility to the virus, preventing outbreaks and improving herd health. Analysts estimate PRP commercialization could triple PIC EBIT within a decade, driven by reduced losses, premium pricing potential, and high-margin royalty-based revenue. Regulatory progress is advancing, with US FDA approval anticipated by 2025 and trials underway in China. Beyond direct sales, PRP opens new licensing opportunities with major global producers, generating recurring revenue streams. Additionally, the underlying gene-editing platform for PRP has potential applications for combating other swine diseases, further expanding the technology’s commercial impact.

","video":null,"video_iframe_url":null}],"company_contents":[{"theme":"Key investor materials","contents":[{"title":"Genus Values Launch Video Montage","content":"https://www.youtube.com/watch?v=YsZuKefosEQ&t=20s","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/YsZuKefosEQ?start=20","showcase_company_content_theme_id":2276},{"title":"H1 25 Trading update","content":"https://ir.q4europe.com/Tools/newsArticleHTML.aspx?solutionID=3694&customerKey=genus&storyID=16331634&language=en","type":"article","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2276},{"title":"FY24 Investor Presentation","content":"https://www.genusplc.com/media/2152/genus_fy24-full-results-final-v2.pdf","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2276},{"title":"Annual Report 2024","content":"https://www.genusplc.com/media/2187/genus-plc-ar24.pdf","type":"pdf","description":null,"content_iframe_url":null,"showcase_company_content_theme_id":2276}]}],"external_insights":[{"theme":"PIC - Gene Edited Pigs","contents":[{"title":"The Mizzou Advantage: Gene Edited Pigs","content":"https://www.youtube.com/watch?v=Nxoz4IVV_00","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/Nxoz4IVV_00?start=undefined","showcase_external_insight_theme_id":2239},{"title":"Gene-edited pigs resistant to deadly PRRS virus","content":"https://www.youtube.com/watch?v=IY1ji4uYboM","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/IY1ji4uYboM?start=undefined","showcase_external_insight_theme_id":2239},{"title":"Poised to be the first widely consumed gene edited animals","content":"https://www.science.org/content/article/poised-be-first-widely-consumed-gene-edited-animals-virus-resistant-pigs-trot-toward","type":"article","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2239},{"title":"The Squeal, by PIC.com","content":"https://open.spotify.com/embed/show/2NuRgs4iKGP17j9tZaVBot","type":"podcast","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2239}]},{"theme":"ABS - Gene Edited Cows","contents":[{"title":"Gene-Edited Cows Approved to be Sold in U.S","content":"https://www.youtube.com/watch?v=AojMPNGik_Y","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/AojMPNGik_Y?start=undefined","showcase_external_insight_theme_id":2240},{"title":"GENEadvance - Advance your herd's performance","content":"https://www.youtube.com/watch?v=wOBuwEJ3M5Q","type":"video","description":"Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.","content_iframe_url":"https://www.youtube.com/embed/wOBuwEJ3M5Q?start=undefined","showcase_external_insight_theme_id":2240},{"title":"Scientists are trying to get cows pregnant with synthetic embryos","content":"https://www.technologyreview.com/2024/05/06/1092055/scientists-are-trying-to-get-cows-pregnant-with-synthetic-embryos/","type":"article","description":"Can animals be made without sperm or eggs? The answer could upend our ideas about what life is.","content_iframe_url":null,"showcase_external_insight_theme_id":2240},{"title":"Gene editing cows for disease resistance","content":"https://open.spotify.com/embed/episode/56Kboq1CfKnYKFAO8YUtT9","type":"podcast","description":null,"content_iframe_url":null,"showcase_external_insight_theme_id":2240}]}],"experts":[{"id":3059,"name":"The Roslin Institute","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1739873375.jpeg","expertise":"An Animal Sciences Research Institute","audience":"25k","x_link":"https://x.com/roslininstitute","linkedin":"https://www.linkedin.com/company/roslin-institute/","website":"https://vet.ed.ac.uk/roslin","quotes":[{"id":4262,"showcase_expert_id":3059,"platform":"article","type":"text","content":"\"We have created pigs resistant to porcine reproductive and respiratory syndrome. The number of farmers going bankrupt because of this disease is enormous\"","cta_label":"Read more","cta_link":"https://english.elpais.com/science-tech/2024-10-13/from-cloning-to-crispr-the-center-that-created-dolly-designs-epidemic-resistant-animals.html","title":null}]},{"id":3060,"name":"Centre for Tropical Livestock Genetics and Health","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1739874083.jpeg","expertise":"Supports partnership programmes that aim to improve livestock-based livelihoods in the tropics","audience":"7k","x_link":"https://x.com/ctlgh_info","linkedin":"https://www.linkedin.com/company/ctlgh/?originalSubdomain=uk","website":"https://www.ctlgh.org/","quotes":[{"id":4263,"showcase_expert_id":3060,"platform":"article","type":"text","content":"\"An opportunity to improve agriculture and food systems at a time of population growth and changing climate\"","cta_label":"Read more","cta_link":"https://phys.org/news/2025-02-network-genetic-pathway-productive-climate.html#google_vignette","title":null}]},{"id":3061,"name":"Marco Winters","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1739881461.jpeg","expertise":"Head of Animal Genetics at AHDB","audience":"2k","x_link":"https://x.com/marco_winters","linkedin":"https://www.linkedin.com/in/marco-winters-44087020/?originalSubdomain=uk","website":null,"quotes":[{"id":4264,"showcase_expert_id":3061,"platform":"article","type":"text","content":"\"Genetic gains in dairy are happening faster than ever before\"","cta_label":"Read more","cta_link":"https://www.farmersguardian.com/news/4402904/british-cattle-breeding-conference-safe-effective-breeding-decisions","title":null}]}],"catalysts":[{"id":3454,"showcase_id":1497,"type":"short","description":"

Anticipated PRP approvals in the US and Colombia could catalyze revenue growth.
Concurrently, Phase II of the ABS VAP is set to deliver additional £10m in savings through operational enhancements and productivity improvements.
Expanded IntelliGen deployments in emerging markets will further bolster ABS’s recovery.

","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null},{"id":3455,"showcase_id":1497,"type":"medium","description":"

The commercial rollout of PRP in China through the BCA joint venture is expected to generate significant revenue, supported by high demand for disease-resistant pigs.
Further adoption of IntelliGen following legal resolutions is poised to increase ABS’s market share, while royalty-based models in Asia will drive recurring revenues.

","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null},{"id":3456,"showcase_id":1497,"type":"long","description":"

Full global adoption of PRP technology, including in Latin America and Southeast Asia, is projected to unlock substantial growth.
Additionally, new gene-editing solutions targeting bovine respiratory disease, heat tolerance, and aquaculture genetics will diversify revenue streams and solidify Genus’s position as a market leader.

","cta_name":null,"cta_link":null,"video":null,"video_iframe_url":null}],"ceo_interviews":[{"id":1705,"showcase_id":1497,"title":null,"video":"https://www.youtube.com/watch?v=N4XtkL21USw","video_iframe_url":"https://www.youtube.com/embed/N4XtkL21USw?start=undefined","cover_image":null}],"faqs":[{"id":3780,"showcase_id":1497,"question":"How transformative is PRP?","answer":"

Analysts project that PRP could triple PIC EBIT within 10 years, driven by reduced PRRS-related losses, recurring royalty revenues, and high-margin licensing agreements. The technology’s ability to prevent PRRS, which costs the pork industry billions annually, positions it as a major industry disruptor. PRP’s scalability extends to both large-scale commercial operations and smaller producers through licensing programs. Furthermore, PRP’s gene-editing platform could be extended to address other swine diseases, enhancing its long-term value proposition. Early trials in China and progress toward US FDA approval, expected by 2025, indicate strong commercialization potential.

","video":null,"video_iframe_url":null},{"id":3781,"showcase_id":1497,"question":"How sustainable is ABS’s recovery?","answer":"

ABS’s resurgence follows years of underperformance due to market competition and operational inefficiencies. The turnaround is anchored in record IntelliGen adoption rates, driven by the technology’s proven ability to boost herd productivity through precise sexed-semen solutions. Growing beef-on-dairy demand, especially in North and Latin America, is creating new revenue streams. Additionally, the Value Acceleration Programme (VAP) has delivered £10m in annualized savings through supply chain improvements and operational efficiencies, with Phase II projected to generate an additional £10m by enhancing customer engagement and digital services. Expansion in Asia and Latin America is unlocking new markets, positioning ABS for long-term, sustainable growth.

","video":null,"video_iframe_url":null},{"id":3782,"showcase_id":1497,"question":"How is Genus handling gene-editing concerns?","answer":"

Genus is proactively addressing consumer and regulatory concerns through a multi-faceted strategy. It is leading public education campaigns to highlight the sustainability and animal welfare benefits of gene-edited livestock. Collaborations with regulatory authorities are advancing clearer labeling standards, ensuring consumer transparency. Additionally, partnerships with major food retailers are facilitating transparent supply chains, helping gene-edited products reach consumers with clear, informative labeling.

","video":null,"video_iframe_url":null},{"id":3783,"showcase_id":1497,"question":"How is Genus reducing reliance on China?","answer":"

Genus is strategically diversifying its market exposure by expanding operations in Latin America and Southeast Asia, regions experiencing rising protein consumption. The company is also implementing royalty-based revenue models in Asia to generate stable, recurring income while mitigating operational risks. Additionally, Genus is developing new partnerships with global producers to access untapped markets and reduce dependence on the Chinese market.

","video":null,"video_iframe_url":null},{"id":3784,"showcase_id":1497,"question":"What’s beyond PRP for Genus?","answer":"

Genus is expanding its R&D pipeline beyond PRP, targeting major livestock challenges with gene-editing solutions. Active projects include developing bovine genetics for respiratory disease resistance, improving feed efficiency to reduce production costs, and creating heat-tolerant cattle breeds for climate-stressed regions. Furthermore, Genus is entering the aquaculture genetics market, where disease resistance and enhanced breeding programs are opening new revenue opportunities. Collectively, these initiatives position Genus to drive long-term growth and innovation beyond its current product portfolio.

","video":null,"video_iframe_url":null}],"researches":[],"articles":[{"id":2504,"showcase_id":1497,"title":"Frontiers | Pigs lacking the SRCR5 domain of CD163 protein demonstrate heritable resistance to the PRRS virus and no changes in animal performance from birth to maturity","description":"Porcine reproductive and respiratory syndrome (PRRS) is one of the world’s most persistent viral pig diseases, with a significant economic impact on the pig ...","link":"https://www.frontiersin.org/journals/genome-editing/articles/10.3389/fgeed.2024.1322012/full","date":null}],"team_members":[{"id":3041,"showcase_id":1497,"name":"Iain Ferguson","role":"Non-Executive Chairman","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1739883286.jpeg","linkedin":null,"x_link":null,"description":"

Appointed in July 2020, Iain Ferguson brings extensive board, governance, and leadership experience. He has a strong background in commercial, science, and agribusiness sectors, particularly in consumer goods and food industries. His deep understanding of capital markets and investor sentiment further enhances his leadership role. Currently, he serves as Chairman of Crest Nicholson Holdings plc and Personal Assets Trust plc, and as Pro Chancellor of Cranfield University. His past roles include Chairman of Berendsen plc and Stobart Group Ltd, and Chief Executive of Tate & Lyle plc.

"},{"id":3042,"showcase_id":1497,"name":"Jorgen Kokke","role":"CEO","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1739883391.jpeg","linkedin":"https://www.linkedin.com/in/jorgen-kokke-5808274/","x_link":null,"description":"

Joining Genus in May 2023, Jorgen Kokke has over 14 years of global leadership experience in the food and agriculture sectors. He previously held senior positions at Ingredion Incorporated, including Executive Vice President & President Americas, and President of Asia Pacific and EMEA. His leadership at Ingredion's North and South American businesses focused on growth through R&D-led innovation and operational excellence. He holds a Master's in Economics from the University of Amsterdam.

"},{"id":3043,"showcase_id":1497,"name":"Alison Henriksen","role":"CFO","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1739883439.jpeg","linkedin":"https://www.linkedin.com/in/alisonhenriksen/?originalSubdomain=uk","x_link":null,"description":"

Appointed in January 2020, Alison Henriksen has over 25 years of experience in finance, mergers and acquisitions, business transformation, and investor relations across Europe, Australia, Asia, the US, and South Africa. She has a proven track record in both public and privately held organizations, spanning B2B and B2C sectors. Alison is a qualified Chartered Accountant, having trained with Ernst & Young. Her previous roles include CFO of V.Group, Finance Director at Compass Group plc, and CFO of Specialty Fashion Group Ltd.

"},{"id":3044,"showcase_id":1497,"name":"Lysanne Gray","role":"Non Executive Director","image":"https://curation-api-production-assets.s3.eu-west-2.amazonaws.com/5/1739883532.jpeg","linkedin":null,"x_link":null,"description":"

Lysanne Gray was appointed to the board in April 2016 and serves as the Chair of the Audit & Risk Committee, while also being a member of the Remuneration and Nomination Committees. She brings significant expertise in risk management, audit, business operations, acquisitions and disposals, and corporate governance, particularly within the food sector. A qualified Chartered Accountant, Lysanne is the Board’s Sustainability Sponsor and one of its designated Workforce Engagement Directors. She has held global leadership roles at Unilever, including Executive Vice President of Sustainable Business Performance and Reporting, Financial Controller, Chief Auditor, and Chief Financial Officer of Unilever’s global food service business.

"}],"showcase_stocks":{"id":1387,"showcase_id":1497,"exchange":"LON","symbol":"GNS","price":1968,"change_percent":-0.81,"average_volume":179518,"marketcap":1299604027,"pe_ratio":0,"raise_amount":null,"equity_offered":null,"valuation":null,"revenue":null,"market_opportunity":null,"raise_amount_currency":null,"valuation_currency":null,"revenue_currency":null,"market_opportunity_currency":null,"target_price":null,"price_target_disclaimer":null},"stock_symbol":"LSE:GNS","exchange":"LON","symbol":"GNS","price":1968,"change_percent":-0.81,"average_volume":179518,"marketcap":1299604027,"pe_ratio":0,"raise_amount":null,"equity_offered":null,"valuation":null,"revenue":null,"market_opportunity":null,"raise_amount_currency":null,"valuation_currency":null,"revenue_currency":null,"market_opportunity_currency":null,"target_price":null,"price_target_disclaimer":null,"target_price_change_percentage":null,"buy":[{"id":1165,"showcase_id":1497,"type":"buy","title":"PIC (porcine) Market Share Growth","caption":"PIC's market share is expanding with tech advancements and strategic positioning in China and Latin America, boosted by digital breeding and disease-resistant genetics."},{"id":1166,"showcase_id":1497,"type":"buy","title":"ABS (bovine) Recovery","caption":"ABS is showing progress with operational efficiencies, better supply chain strategies, and growing markets in North and Latin America, fueled by digital tech adoption."},{"id":1167,"showcase_id":1497,"type":"buy","title":"PRP Potential","caption":"PRP’s gene-editing innovation could reduce pork industry losses, enabling premium pricing and royalties, with licensing opportunities for long-term growth."}],"sell":[{"id":1168,"showcase_id":1497,"type":"sell","title":"Disease Risk","caption":"Outbreaks like ASF or PRRS pose risks to operational stability, potentially disrupting business and profitability despite biosecurity measures."},{"id":1169,"showcase_id":1497,"type":"sell","title":"Gene-Edited Meat Acceptance","caption":"Public skepticism and regulatory barriers could slow gene-edited meat adoption, limiting PRP’s market potential."},{"id":1170,"showcase_id":1497,"type":"sell","title":"China Exposure","caption":"Genus’s reliance on China’s pork market adds geopolitical and market risks. Disruptions could impact revenues, highlighting the need for diversification."}],"key_risks":[{"id":496,"showcase_id":1497,"title":"Disease Risk to Nucleus Herds","description":"

Outbreaks of ASF, PRRS, or foot-and-mouth disease could severely disrupt operations. To mitigate this, Genus has implemented advanced biosecurity protocols, diversified its nucleus herds geographically, and invested in rapid diagnostic technologies.

","video":"https://google.com","video_iframe_url":null},{"id":497,"showcase_id":1497,"title":"Consumer Acceptance of Gene-Edited Meat:","description":"

Public resistance and regulatory challenges could slow PRP adoption. Genus is addressing these concerns through targeted consumer education campaigns, partnerships with retailers for transparent labeling, and advocacy for clear regulatory standards.

","video":"https://google.com","video_iframe_url":null},{"id":498,"showcase_id":1497,"title":"China Exposure","description":"

Heavy reliance on China’s pork market exposes Genus to geopolitical and market volatility. To reduce dependency, Genus is expanding its royalty-based revenue model in Asia and accelerating growth initiatives in Latin America and Southeast Asia.

","video":"https://google.com","video_iframe_url":null}],"industries":[{"id":205,"industry_id":6,"name":"Healthcare"}],"tag":null,"prompts":[{"id":953,"showcase_id":1497,"sequence":1,"question":"What are the company's revenues?"},{"id":954,"showcase_id":1497,"sequence":2,"question":"Is the company profitable?"},{"id":955,"showcase_id":1497,"sequence":3,"question":"How much cash does it have?"},{"id":956,"showcase_id":1497,"sequence":4,"question":"Who are the top 5 biggest shareholders?"},{"id":957,"showcase_id":1497,"sequence":5,"question":"Tell me about the CEO's background"},{"id":958,"showcase_id":1497,"sequence":6,"question":"Who are the major competitors?"},{"id":959,"showcase_id":1497,"sequence":7,"question":"What is the market opportunity?"}]},"slug":"Genus-24053"}]